208 related articles for article (PubMed ID: 20458280)
41. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
42. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
Matalińska J; Świć A; Lipiński P; Misicka A
Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
[TBL] [Abstract][Full Text] [Related]
43. NK-1 receptor antagonists: a new generation of anticancer drugs.
Munoz M; Covenas R
Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565
[TBL] [Abstract][Full Text] [Related]
44. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
45. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
Muñoz M; Coveñas R
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962202
[TBL] [Abstract][Full Text] [Related]
46. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines.
Muñoz M; Rosso M; Pérez A; Coveñas R; Rosso R; Zamarriego C; Piruat JI
Neuropeptides; 2005 Aug; 39(4):427-32. PubMed ID: 15939468
[TBL] [Abstract][Full Text] [Related]
47. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Hesketh PJ; Van Belle S; Aapro M; Tattersall FD; Naylor RJ; Hargreaves R; Carides AD; Evans JK; Horgan KJ
Eur J Cancer; 2003 May; 39(8):1074-80. PubMed ID: 12736106
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist.
Yoshino-Furukawa T; Maeda Y; Kikuchi A; Sakuma H; Imazumi K; Yamakuni H; Sogabe H; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2013; 36(1):76-81. PubMed ID: 23302639
[TBL] [Abstract][Full Text] [Related]
49. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis.
Martinez AN; Burmeister AR; Ramesh G; Doyle-Meyers L; Marriott I; Philipp MT
J Neuroinflammation; 2017 Feb; 14(1):37. PubMed ID: 28202084
[TBL] [Abstract][Full Text] [Related]
50. Neurokinin-1 receptor: a new promising target in the treatment of cancer.
Muñoz M; Coveñas R
Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671
[TBL] [Abstract][Full Text] [Related]
51. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
[TBL] [Abstract][Full Text] [Related]
52. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
53. Safety of neurokinin-1 receptor antagonists.
Muñoz M; Coveñas R
Expert Opin Drug Saf; 2013 Sep; 12(5):673-85. PubMed ID: 23706125
[TBL] [Abstract][Full Text] [Related]
54. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
[TBL] [Abstract][Full Text] [Related]
55. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.
Warr D
Expert Opin Pharmacother; 2006 Aug; 7(12):1653-8. PubMed ID: 16872268
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
[TBL] [Abstract][Full Text] [Related]
57. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
[TBL] [Abstract][Full Text] [Related]
58. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
59. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
AlAlikhan A; Ghahremanloo A; Javid H; Ebrahimi S; Hashemy SI
Cell Biochem Biophys; 2022 Dec; 80(4):819-827. PubMed ID: 36197642
[TBL] [Abstract][Full Text] [Related]
60. Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-
Ghahremanloo A; Javid H; Afshari AR; Hashemy SI
Biomed Res Int; 2021; 2021():1383878. PubMed ID: 34395609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
